NALOXONE HYDROCHLORIDE INJECTION USP 0.4 MG/ML

Indications

• Opioid overdose
• Reversal of opioid-induced respiratory depression

Dosage

Adults: For opioid overdose reversal, the usual adult dose of naloxone is 0.4 to 2 mg administered intravenously, intramuscularly, or subcutaneously. If there is no response after 2 to 3 minutes, additional doses may be given. The maximum single dose is usually 10 mg. In cases of suspected opioid overdose where the opioid type is unknown, naloxone may be administered while awaiting emergency assistance.

Mechanism of action

Naloxone acts as a competitive antagonist at mu, kappa, and sigma opioid receptors in the central nervous system (CNS), with the highest affinity for the mu receptor. By blocking these receptors, naloxone reverses the effects of opioids, including respiratory depression and sedation. Its antagonistic effects are prominent in individuals who have consumed opioids, while having negligible impact in opioid-naive patients.

Pharmacodynamics

Naloxone is specifically indicated for the reversal of opioid overdose. It can restore respiratory function and increase arterial oxygen levels when administered in cases of opioid toxicity. Due to its shorter duration of action compared to most opioids, repeated doses may be necessary to maintain reversal effects. Patients receiving naloxone may experience symptoms of opioid withdrawal if they are dependent on opioids.

Pharmacokinetics

Naloxone is rapidly absorbed following parenteral administration, with peak plasma concentrations occurring within 13 to 30 minutes. The drug undergoes extensive hepatic metabolism, primarily via glucuronidation, and has a relatively short half-life, necessitating careful monitoring and possible repeated dosing in opioid overdose situations. The elimination half-life of naloxone is generally around 30 to 90 minutes, depending on the route of administration.

Adverse effects

• Nausea
• Vomiting
• Sweating
• Tachycardia
• Hypertension
• Opioid withdrawal symptoms

Interactions

• Opioid analgesics - may precipitate withdrawal symptoms
• Other CNS depressants - may counteract the effects of naloxone

Precautions

• Use with caution in patients with a history of opioid dependence
• Monitor for withdrawal symptoms in opioid-dependent patients
• Consider the possibility of multiple drug overdoses

Pregnancy

Naloxone should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Naloxone is excreted in breast milk. Caution should be exercised when naloxone is administered to a nursing mother.

Storage

Store at room temperature, away from light and moisture. Do not freeze.

Formulations

• Injection: 0.4 mg/mL in 1 mL ampoules
• Intranasal spray: 4 mg/0.1 mL

Indications

• Acute opioid overdose
• Opioid toxicity management in emergency settings

Dosage

Children: Neonates: Initially 10 micrograms/kg, repeated every 2-3 minutes if required. For children aged 1 month to 11 years: Initially 100 micrograms/kg, maximum of 2 mg, may be repeated if no response.

Adults: Initially, 400 micrograms, then 800 micrograms if no response. Further doses of 2 mg may be given if necessary, particularly in seriously poisoned patients; maximum of 50 mg for up to 2 doses at 1 minute intervals.

Mechanism of action

Naloxone acts as a competitive antagonist at mu, kappa, and delta opioid receptors. Binding to these receptors blocks the effects of opioids, including respiratory depression and sedation, by preventing opioids from exerting their agonistic effects.

Pharmacodynamics

The pharmacodynamic profile of naloxone includes rapid reversal of opioid-induced respiratory depression and sedation. The onset of action occurs within minutes following intravenous administration, and its effects typically last for 30 to 90 minutes, depending on the dose and the specific opioids involved.

Pharmacokinetics

Naloxone is rapidly absorbed, with a peak plasma concentration occurring approximately 15 to 30 minutes after administration. It is extensively metabolized in the liver, primarily by conjugation to naloxone-3-glucuronide, which is inactive. The elimination half-life is approximately 30 to 81 minutes, which is shorter than many opioids, hence the need for repeated doses in cases of opioid overdose.

Adverse effects

• Nausea
• Vomiting
• Sweating
• Tachycardia
• Hypertension
• Pulmonary edema
• Seizures
• Withdrawal symptoms in opioid-dependent patients

Interactions

• May precipitate withdrawal symptoms in patients dependent on opioids
• Interactions with drugs that affect respiratory function

Precautions

• Use with caution in patients with cardiovascular disease
• Monitor respiratory function closely after administration
• Excessive doses can have an anticoagulant effect

Pregnancy

Naloxone should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It may precipitate withdrawal in opioid-dependent pregnant women.

Breast-feeding

Naloxone is excreted in breast milk; caution should be exercised when administered to a nursing mother.

Storage

Store at room temperature, away from light. Do not freeze. Protect from light.

Formulations

• Solution for injection

Mechanism of action

Naloxone is a competitive inhibitor of the µ-opioid receptor. Naloxone antagonizes the action of opioids, reversing their effects. If a patient has not taken opioids, naloxone does not have a significant effect on patients. Naloxone hydrochloride is essentially a pure opiate antagonist. The precise mechanism of action of the opiate antagonist effects of naloxone is not fully understood. Naloxone is thought to act as a competitive antagonist at mu, kappa, and sigma opiate receptors in the CNS; it is thought that the drug has the highest affinity for the mu receptor. In contrast to levallorphan or nalorphine, naloxone has little or no agonistic activity. When administered in usual doses to patients who have not recently received opiates, naloxone exerts little or no pharmacologic effect. Even extremely high doses of the drug (10 times the usual therapeutic dose) produce insignificant analgesia, only slight drowsiness, and no respiratory depression, psychotomimetic effects, circulatory changes, or miosis. In patients who have received large doses of morphine or other analgesic drugs with morphine-like effects, naloxone antagonizes most of the effects of the opiate. There is an increase in respiratory rate and minute volume, arterial PCO2 decreases toward normal, and blood pressure returns to normal if depressed. Unlike nalorphine or levallorphan, naloxone antagonizes mild respiratory depression caused by small doses of opiates. Because the duration of action of naloxone is generally shorter than that of the opiate, the effects of the opiate may return as the effects of naloxone dissipate. Naloxone antagonizes opiate-induced sedation or sleep. Reports are conflicting on whether or not the drug modifies opiate-induced excitement or seizures. Heat shock protein (HSP)60 is primarily a mitochondrial protein. Previous experiments have found that changes in the location of intracellular HSP60 have been associated with apoptosis. Extracellular HSP60 mediates apoptosis via its ligand, Toll-like receptor (TLR)-4. TLR-4 is an important factor expressed on microglia, with a central role in generating neuroimmune responses in the pathogenesis of neurodegenerative disorders. Naloxone is a highly effective nonselective opioid receptor antagonist, and has been reported to be pharmacologically beneficial for the treatment of brain diseases through inhibiting microglia activation. However, the mechanisms underlying these beneficial effects of naloxone remain poorly understood. The present study aimed to investigate the role of HSP60 in the neuroprotective effects of naloxone on the production of proinflammatory mediators in lipopolysaccharide (LPS)-stimulated BV2 murine microglial cells and the possible signaling pathways involved. The results demonstrated that naloxone significantly inhibited the expression and release of HSP60 in BV2 cells. The expression levels of heat shock factor (HSF)-1 were upregulated in LPS-activated BV2 cells, which indicated that the increased expression of HSP60 was driven by HSF-1 activation. However, increased HSF-1 levels may be downregulated by naloxone. The levels of TLR-4 were elevated in activated BV2 cells, and then inhibited by naloxone. Activation of TLR-4 is characterized by activation of nuclear factor-kB (NF-kB) followed by the production of various proinflammatory and neurotoxic factors. Data from the present study demonstrated that naloxone reduced the expression levels of NF-kB and its upstream protein caspase-3, and reduced the LPS-induced production of nitric oxide, inducible nitric oxide synthase, tumor necrosis factor a, interleukin-1beta and interleukin-6 in BV2 microglia. In light of this data, it was concluded that naloxone may exert its neuroprotective and anti-inflammatory effects by inhibiting microglia activation through a HSP60-TLR-4-NF-kB signaling pathway. Phosphoinositide 3-kinase (PI3K) delta and gamma (the p110delta and p110gamma isoforms of PI3K) actively participate in the process of

Pharmacodynamics

Naloxone is an opioid receptor antagonist indicated in the reversal of opioid overdoses. Naloxone has a shorter duration of action than opioids and multiple doses may be required. The therapeutic window of naloxone is wide, as it has no effect if a patient has not taken opioids. Patients treated with naloxone may experience opioid withdrawal and a person administering naloxone should be aware that reversal of opioid overdoses may not resolve all the symptoms a patient is experiencing if other drugs are involved.